18 January 2021 – GV Returns for EQRx’s $500m Series B

The Big Ones

EQRx formally launched a year ago with $200m from investors including GV and Nextech, and all its series A investors have now returned for a $500m series B round. The startup is collaborating with stakeholders including pharmaceutical companies to develop more affordable medicines, with late-stage cancer drugs a particular focus. It is also part of an increasingly diverse portfolio of early-stage life sciences companies in GV’s portfolio.

Mobile network operator Orange is the latest corporate to spin off its venture capital unit with a healthy addition to its funding allocation. Orange Ventures will henceforth operate as an independent entity, and has received $426m in capital from its former parent company in addition to the portfolio of its predecessor, Orange Digital Ventures. That portfolio includes Monzo, Raisin and Actility.

Qualcomm Technologies has agreed to buy silicon chip technology developer Nuvia for $1.4bn less than two years after it was founded. Nuvia had raised $293m across two rounds pre-acquisition, both of which included Dell’s corporate venturing subsidiary, Dell Technologies Capital. It could well be an early marker of some of the M&A activity that will spring up as 5G technology begins to get a real foothold in the mainstream.

Dice Molecules, a US-based biopharmaceutical spinout of Stanford University, has closed an $80m series C round featuring spinout-focused investment firm Osage University Partners. RA Capital Management led the round, which also attracted Sanofi Ventures and Alexandria Venture Investments on behalf of pharmaceutical firm Sanofi and real estate investment trust Alexandria Real Estate Equities. Founded in 2014, Dice Molecules has developed a drug discovery platform leveraging technology dubbed DNA-encoded library, which it hopes will make it possible to target a range of conditions with oral treatments rather than requiring injections. Its lead asset is aimed at psoriasis, and the company has been collaborating with Sanofi since 2016.

Deals

WeWork aside, Vision Fund’s biggest failure was perceived as OneWeb, the satellite internet operator that declared bankruptcy early last year after SoftBank had pumped some $2bn into the company. However, Bharti Enterprises joined the UK government to buy it for $1bn in the resulting auction, and now SoftBank is back, putting in $350m of a $400m investment expected to help OneWeb complete its initial satellite constellation. It will come out with a 30% stake, and the other $50m was put up by another pre-bankruptcy investor.

Online fitness was earmarked as one of the big growth sectors in our 2021 preview, and the first company in the space to raise big money this year is Keep, which has bagged $360m in series F funding at a valuation of about $2bn. SoftBank Vision Fund led the livestreamed fitness class provider’s latest round, which also featured existing backers Tencent and Bertelsmann Asia Investments.

Autonomous driving software developer WeRide raised $200m in series B funding from bus manufacturer Yutong Group last month and it has now added $110m to close the round at $310m. The round comes after earlier funding provided by investors including Nvidia GPU Ventures, SenseTime, Johnson Electric and Alliance Ventures.

Digital lending software provider Blend has closed a $300m series G round that doubled its valuation to $3.3bn in just five months, which is very impressive. The round was co-led by Tiger Global and Coatue, though no mention of existing corporate backer Salesforce.

Blend isn’t the only fintech developer to have experienced a huge jump in valuation last week. Cross-border payment platform developer Rapyd has also received $300m, in a series D round also led by Coatue. The series D boosted the valuation of Rapyd, which counts Stripe as an earlier investor, to $2.5bn post-money, more than double that of a year ago.

Tessera Therapeutics is the latest in a series of life sciences startups that have raised nine-figure amounts for their first external rounds, having pulled in $230m for its gene writing technology, which aims to prevent disease by rewriting the genome. The series B round was co-led by SoftBank Vision Fund 2, which may itself be looking to get more involved in the sector.

Elsewhere in China, employee management software provider WorkTrans has announced over $190m in funding, $140m coming in a Tencent-backed series D round. The round was disclosed together with a $50.5m series C round and it increased WorkTrans’ overall funding to approximately $236m. It will support further development of the company’s HR management product, which makes use of deep learning and cloud computing technology.

SoftBank’s $5bn Latin America fund has given it a sizeable foothold on the continent, and it has co-led a $190m round for one of its portfolio companies, furnishing and home decor marketplace MadeiraMadeira. The corporate also led MadeiraMadeira’s last round, in which it secured $110m, and the funding is set to fund the expansion of the company’s brick-and-mortar footprint and a prospective range of own-brand products.

GV was among the participants in a $160m funding round for distributed database technology provider Cockroach Labs that valued it at $2bn. The Alphabet subsidiary has been a Cockroach investor since its $6.3m series A round in 2015 and has been along for every round since, as the company has hiked its total funding to $355m.

Exits

It seems amazing now that just a year ago it looked like the losses suffered by SoftBank’s Vision Fund could have severely impacted its corporate parent as a whole. There have been few bigger winners from the boom in the public markets and VC spaces, and its next exit could be from Auto1. The online car dealership has announced it plans to launch an initial public offering in Frankfurt that could raise some $1.2bn alongside a private placement. Vision Fund invested $565m in Auto1 at a $3.56bn valuation in 2018 and it’s going to be interesting to see how that valuation compares to the company’s market cap when it does float.

Dynamic window producer View announced plans for a reverse merger in November that would be boosted by $300m in PIPE financing. That amount is set to be boosted to $500m after Singaporean sovereign wealth fund GIC committed a further $200m, adding to some $1.8bn in earlier debt and equity financing. That capital was provided by investors including SoftBank Vision Fund 1, Corning and Seagate.

Cryptocurrency services provider Bakkt was launched by financial exchange operator Intercontinental Exchange (ICE) in 2018 and less than three years on, it has agreed to a reverse merger set to value it at $2.1bn once the deal closes. It will also take an NYSE listing and $325m in PIPE financing from investors including ICE. It had raised more than $480m in venture funding from backers also including Microsoft unit M12, PayU and Boston Consulting Group.

Funds

Germany-listed food delivery service Delivery Hero has committed €50m ($61m) to set up an independently-managed, early-stage corporate venture capital firm called DX Ventures. DX Ventures will invest in sectors including on-demand services, food technology, sustainable innovation, artificial intelligence, financial technology and logistics. It will be led by managing director Duncan McIntyre.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0

20 January 2020 – Joby Aviation Raises $590m in Series C to Create Flying Taxis

The Big Ones

Joby Aviation is developing an electric-powered aerial taxi for urban use, a product that would appear to be a big jump into the future even without taking into account sustainability issues concerning its stated aim to serve ‘a billion’ people a day. But corporate investors are taking it seriously and none more than Toyota which invested $394m to lead its $590m series C round.

UPMC Enterprises functions as the investment and innovation arm of University of Pittsburgh Medical Center (which sounds like it’s just the one but actually it’s a system comprised of 40 hospitals) and has built up an 18-strong portfolio alongside investments in internal projects. It looks to be upgrading its activity as well, announcing plans to allocate $1bn in capital through 2024, $800m of which is newly disclosed and $200m has already been dedicated to an immuno-therapy research partnership with the university.

Visa invested in financial data technology provider Plaid just four months ago and must have liked what it saw because it has agreed to acquire financial data technology provider Plaid in a $5.3bn transaction that what will surely be one of the year’s biggest acquisitions of a VC-backed company.

Deals

Xiaohongshu, the social commerce platform also known as Little Red Book, is resuming fundraising activities and is reportedly seeking $400m to $500m at a $6bn valuation. The company secured $300m in a 2018 series D round featuring Tencent and Alibaba at a $3bn valuation and was exploring new funding last year, only to suspend efforts after its app was temporarily pulled from Chinese app stores.

Tradeshift, a provider of supply chain-management and payment processing software, has raised $240m in debt and equity financing from undisclosed new and existing investors. No word on the former but its existing backers include American Express Ventures, Wipro Ventures, PayPal, Intuit, CreditEase Fintech Investment Fund and HSBC.

EQRx has launched with $200m in series A funding from GV and Nextech and a mission to develop more affordable copies of drugs already on the market. In contrast to licensed biosimilars, the startup will use advanced technology to create its own patent-protected versions, in theory providing more accessible medicines while generating more profit.

Electric vehicle technology developer Arrival has been relatively stealthy since it was founded in 2015 but has disclosed a $112m investment by carmaker Hyundai and subsidiary Kia. The funding came as part of a strategic collaboration through which Arrival will provide technology for Hyundai’s own mobility and EV initiatives.

Emendo Biotherapeutics is developing genetic medicines using a proprietary platform that utilises Crispr gene editing and protein engineering. It has also raised $61m in a series B round led by biopharmaceutical company AnGes, which is developing its own genetic therapies and which plans to work with Emendo on certain indications.

Funds

China-based insurer Taiping, has formed a $1bn investment vehicle called TP-CICC GBA Investment Master Fund in partnership with China International Capital Corporation’s CICC Capital division. The fund will target companies based in China’s Bay Area that are developing technology for the financial, healthcare, consumer and insurance sectors among others.

Saudi Aramco has pumped its IPO up to $29.4bn, making it the largest in history, and the petrochemical producer is also looking to expand its corporate venturing activity. The corporate is reportedly lining up a $500m second fund for its Saudi Aramco Energy Ventures unit that will likely be launched later this year.

IT services firm Wipro launched its Wipro Ventures subsidiary in 2015 with a $100m fund that has so far invested in 16 companies and exited two – one of which was Palo Alto Networks’ $560m acquisition of Demisto. The unit has now announced a second fund with an upgraded size of $150m.

Exits

Teladoc has agreed to buy telehealth technology producer InTouch Health for $150m in cash and $450m in shares. The company had raised less than $100m in funding, $6m of which was supplied by iRobot through a 2012 expansion to a partnership agreement.

Suzhou Zelgen Biopharmaceuticals has priced a $294m initial public offering on the Shanghai Stock Exchange’s Star Market that is impressively sized despite not meeting its initial target of $346m. The cancer therapy developer had raised money across five rounds including a $62m series B two years ago that included insurance firm Minsheng Life.

NGP Capital has exited on-device AI technology developer Xnor.ai in an acquisition by Apple reportedly sized around the $200m mark. NGP Capital was spun off from Nokia but the corporate is still a prominent backer, and the deal will be pulling in some decent returns considering Xnor had disclosed less than $15m in funding pre-acquisition.

Casper Sleep, one of a wave of high-end mattress developers to launch in recent years, has filed to go public having raised $340m in venture funding from investors including Target. It is set to beat corporate-backed competitors like Helix and Eve Sleep to the public markets, though it’s as yet unclear whether the $67m loss it suffered in the first nine months of 2019 will affect its valuation, which stood at $1.1bn as of last March.


“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0